Use of vegf inhibitors for the treatment of human cancer

Details Use of vegf inhibitors for the treatment of human cancer Use of vegf inhibitors for the treatment of human cancer

A - Human Necessities

61

K

A61K 38/17 (2006.01)

Patent

CA 2567686

A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial use of at least approximately 0.3 mglkg of the VEGF antagonist; and (b) administering the patient a plurality of subsequent doses of the VEGF antagonist in an amount that approximately the same or less of the initial dose, wherein the subsequent doses are separated in time from each other by at least one day. The methods of the invention are useful for treating a human cancer selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, breast cancer, prostate cancer, colorectal cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, and melanoma. The invention is further useful for treating a condition which benefits from the reduction of VEGFA and placental growth factor (PLGF).

L'invention concerne une méthode de traitement d'un patient humain souffrant d'un cancer. Cette méthode consiste à administrer une quantité efficace d'un antagoniste piégeant le facteur de croissance endothéliale vasculaire (VEGF), à ce patient. La méthode consiste à: (a) administrer au patient une dose initiale d'au moins 0,3 mg par kg environ de l'antagoniste de VEGF; et (b) administrer à ce patient une pluralité de doses subséquentes de l'antagoniste de VEGF, dans une quantité qui est approximativement identique ou inférieure à la dose initiale, les doses subséquentes étant temporellement séparées les unes des autres d'au moins un jour. Les méthodes de l'invention sont utiles pour traiter un cancer humain sélectionné dans le groupe contenant: un carcinome cellulaire rénal, un carcinome pancréatique, un cancer du sein, un cancer de la prostate, un cancer colorectal, un mésothélium malin, un myélome multiple, un cancer ovarien et un mélanome. L'invention est également utile pour traiter un trouble dans lequel la réduction de VEGFA et du facteur de croissance placentaire (PLGF) est un avantage.

Affiliated with

Also associated with

Rating

Use of vegf inhibitors for the treatment of human cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of vegf inhibitors for the treatment of human cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of vegf inhibitors for the treatment of human cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1493679